Trials / Completed
CompletedNCT04459988
Mechanistic Study of Ocrevus
Enhanced Regulatory Functions of Bregs With Ocrelizumab in Multiple Sclerosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 35 (actual)
- Sponsor
- University of Michigan · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the immune cell and other factor changes with Ocrevus in Multiple Sclerosis (MS) patients. Researchers will recruit 35 participants for this study. Patients will be enrolled from the Multiple Sclerosis Center at the University of Michigan Health System in Ann Arbor. The goal of the study is to understand the role of regulatory B cell, T cell and other factors in mediating the therapeutic effects of Ocrevus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ocrelizumab | Description Needed |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2022-10-25
- Completion
- 2022-10-25
- First posted
- 2020-07-07
- Last updated
- 2024-05-31
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04459988. Inclusion in this directory is not an endorsement.